The Prognostic Role of Platelet-to-Lymphocyte Ratio in Acute Coronary Syndromes: A Systematic Review and Meta-Analysis
Journal of Clinical Medicine · 02.11.2023 · 12 (21) · 6903
DOI: 10.3390/jcm12216903 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 02.11.2023. Verfasst von Michal Pruc und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Public Health, International European University, 03187 Kyiv, Ukraine. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
This study aimed to investigate the potential prognostic role of the platelet-to-lymphocyte (PLR) ratio in patients presenting with suspected acute coronary syndromes (ACS). A systematic search of PubMed Central, Scopus, EMBASE, and the Cochrane Library from conception through 20 August 2023 was conducted. We used odds ratios (OR) as the effect measure with 95% confidence intervals (CIs) for dichotomous data and mean differences (MD) with a 95% CI for continuous data. If I2 was less than 50% or the p value of the Q tests was less than 0.05, a random synthesis analysis was conducted. Otherwise, a fixed pooled meta-analysis was performed. Nineteen studies fulfilled the eligibility criteria and were included in the meta-analysis. PLR was higher in MACE-positive (164.0 ± 68.6) than MACE-negative patients (115.3 ± 36.9; MD = 40.14; 95% CI: 22.76 to 57.52; p < 0.001). Pooled analysis showed that PLR was higher in AMI patients who died (183.3 ± 30.3), compared to survivors (126.2 ± 16.8; MD = 39.07; 95% CI: 13.30 to 64.84; p = 0.003). It was also higher in the ACS vs. control group (168.2 ± 81.1 vs. 131.9 ± 37.7; MD = 39.01; 95% CI: 2.81 to 75.21; p = 0.03), STEMI vs. NSTEMI cohort (165.5 ± 92.7 vs. 159.5 ± 87.8; MD = 5.98; 95% CI: −15.09 to 27.04; p = 0.58), and MI vs. UAP populations (162.4 ± 90.0 vs. 128.2 ± 64.9; MD = 18.28; 95% CI: −8.16 to 44.71; p = 0.18). Overall, our findings confirmed the potential prognostic role of the plate-let-to-lymphocyte (PLR) ratio in patients presenting with suspected acute coronary syndromes (ACS). Its use as a risk stratification tool should be examined prospectively to define its capability for evaluation in cardiovascular patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Public Health, International European University, 03187 Kyiv, Ukraine.
- Henry JN Taub Department of Emergency Medicine, Baylor College of Medicine, Houston, TX 77030, USA.
- Department of Toxicology, Faculty of Pharmacy, Medical University of Gdansk, 80-416 Gdansk, Poland.
- Department of Clinical Research and Development, LUXMED Group, 02-676 Warsaw, Poland.
- Department of Emergency Medicine, Ufuk University Medical Faculty, 06510 Ankara, Turkey.
- Institute of Outcomes Research, Maria Sklodowska-Curie Medical Academy, 00-136 Warsaw, Poland.
ORCID-Profile: Michal Pruc, Frank William Peacock, Damian Swieczkowski, Lukasz Szarpak
Zitieren
APA
Pruc, M., Peacock, F. W., Rafique, Z., Swieczkowski, D., Kurek, K., Tomaszewska, M., Katipoglu, B., Koselak, M., Cander, B., & Szarpak, L. (2023). The Prognostic Role of Platelet-to-Lymphocyte Ratio in Acute Coronary Syndromes: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine, 12(21), 6903. https://doi.org/10.3390/jcm12216903
Vancouver
Pruc M, Peacock FW, Rafique Z, Swieczkowski D, Kurek K, Tomaszewska M, et al. The Prognostic Role of Platelet-to-Lymphocyte Ratio in Acute Coronary Syndromes: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine. 2023;12(21):6903. doi:10.3390/jcm12216903
BibTeX
@article{Pruc2023,
author = {Pruc, Michal and Peacock, Frank William and Rafique, Zubaid and Swieczkowski, Damian and Kurek, Krzysztof and Tomaszewska, Monika and Katipoglu, Burak and Koselak, Maciej and Cander, Basar and Szarpak, Lukasz},
title = {The Prognostic Role of Platelet-to-Lymphocyte Ratio in Acute Coronary Syndromes: A Systematic Review and Meta-Analysis},
journal = {Journal of Clinical Medicine},
year = {2023},
volume = {12},
number = {21},
pages = {6903},
doi = {10.3390/jcm12216903}
}
EUVIMED